None listed
Conditions
Interventions
Medical Device : This study aims to investigate the difference in pain control when a thermosensitive pain control gel (WELPASS), which is slowly released over 72 hours when injected directly at the s
Sponsors
The Catholic University of Korea, Incheon St. Mary's Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patients who understand and provide written consent to participate in this study, which involves treatment as part of an experimental group receiving both injectable pain medication and a thermosensitive gel applied to the surgical site under a blinded randomized allocation. Additionally, patients must be able to communicate effectively about their pain.
Exclusion criteria
Exclusion criteria: 1. Patients unable to communicate verbally or non-verbally. 2. Patients with pathological pain syndromes, such as Complex Regional Pain Syndrome (CRPS). 3. Patients with a history of treatment at a pain management clinic. 4. Patients with adverse reactions to injectable pain medications. 5. Patients who do not consent to the use of IV PCA. 6. Patients with hypersensitivity to components of the thermosensitive gel, such as Poloxamer or Sodium Alginate. 7. Patients with lymphatic fluid disorders, coagulation disorders, or severe liver or kidney diseases. 8. Pregnant women. 9. Vulnerable subjects, including students, employees, or soldiers who may face disadvantages from superiors in the hierarchy, individuals with cognitive impairments (including those medically incapable of providing consent), patients with incurable or terminal diseases, foreigners, or patients in emergency situations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of WELPASS in Pain Control | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of WELPASS | — |
Countries
Korea, Republic of
Contacts
Public Contactbowon kim
The Catholic University of Korea, Incheon St. Mary's Hospital
Outcome results
None listed